PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer

PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer

Saved in:

Bibliographic Details
Main Authors:	Xiangyu Qiu, Zhaoan Yu, Xiaoqing Lu, Xin Jin, Jinrong Zhu, Rongxin Zhang
Format:	Article
Language:	English
Published:	China Anti-Cancer Association 2024-11-01
Series:	Cancer Biology & Medicine
Online Access:	https://www.cancerbiomed.org/content/21/11/970
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti‐Lag‐3 via reducing FGL1 expression
by: Jianchu Wang, et al.
Published: (2020-10-01)

Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
by: Sandip P. Patel, et al.
Published: (2025-01-01)

Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer
by: Zong Sheng Guo, et al.
Published: (2020-05-01)

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
by: Chenyu Mao, et al.
Published: (2024-12-01)

Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells
by: Susan N Christo, et al.
Published: (2024-01-01)

Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
by: Bo-Kyeong Jung, et al.
Published: (2020-10-01)

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
by: Louis Boon, et al.
Published: (2020-10-01)

Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination
by: Kamran Kaveh, et al.
Published: (2021-10-01)

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
by: Menglei Jin, et al.
Published: (2024-11-01)

Pathological mechanisms and advances in neoadjuvant PD-1 blockade combined with chemotherapy for head and neck cancer
by: Yun-jing Hou, et al.
Published: (2024-12-01)

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
by: Tuba N. Gide, et al.
Published: (2023-12-01)

A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
by: Jin Bian, et al.
Published: (2022-01-01)

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
by: Diwakar Davar, et al.
Published: (2015-01-01)

Dual Indicators of Well‐Being: Leading With Fulfillment, Lagging With Burnout
by: Laxmi S. Mehta, et al.
Published: (2024-09-01)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
by: Rangarirai Makuku, et al.
Published: (2021-01-01)

The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade
by: Yuchen Zhang, et al.
Published: (2024-11-01)

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer
by: Qi Xie, et al.
Published: (2024-11-01)

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
by: Xin Zhang, et al.
Published: (2020-10-01)

Deciphering the mechanisms of long non-coding RNAs in ferroptosis: insights into its clinical significance in cancer progression and immunology
by: Shengming Ou, et al.
Published: (2025-01-01)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
by: Alfred Zippelius, et al.
Published: (2022-11-01)

Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer
by: Yan Wang, et al.
Published: (2024-12-01)

Alleviating Tumor Hypoxia and Immunosuppression via Sononeoperfusion: A New Ally for potentiating anti-PD-L1 blockade of solid Tumor
by: Guoliang Yang, et al.
Published: (2025-01-01)

Peripheral CX3CR1+ T cells combined with PD-1 blockade therapy potentiates the anti-tumor efficacy for lung cancer
by: Congcong Li, et al.
Published: (2024-12-01)

Methionine restriction promotes the polarization of macrophages towards M1 and the immunotherapy effect of PD-L1/PD-1 blockades by inhibiting the secretion of MIF by gastric carcinoma cells
by: Lin Xin, et al.
Published: (2025-01-01)

SMAC-armed oncolytic virotherapy enhances the anticancer activity of PD1 blockade by modulating PANoptosis
by: Fanghui Chen, et al.
Published: (2025-01-01)

Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy
by: Vishnu Vijay Vijayan, et al.
Published: (2024-12-01)

Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG‐3 and PD‐L1
by: Lishu Zhao, et al.
Published: (2025-01-01)

Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma
by: Marek Pasek, et al.
Published: (2025-01-01)

Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade
by: Ayana Yamagami, et al.
Published: (2024-05-01)

Long-Term Response to PD-1 and CTLA-4 Blockade in an SCLC Patient with Negative PD-L1 Expression on Biopsy: A Case Report
by: Marco Cefalì, et al.
Published: (2023-03-01)

Disrupting EDEM3‐induced M2‐like macrophage trafficking by glucose restriction overcomes resistance to PD‐1/PD‐L1 blockade
by: Shaoyong Peng, et al.
Published: (2025-01-01)

Pembrolizumab (Keytruda) in blockade of PD-1 Pathway to enhance tumor immunity in Oral squamous cell carcinoma
by: P. Kowsalya
Published: (2024-06-01)

Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
by: Fan Sun, et al.
Published: (2024-12-01)

Comparative Analysis of Immunoactivation by Nanosecond Pulsed Electric Fields and PD-1 Blockade in Murine Hepatocellular Carcinoma
by: Maiweilidan Yimingjiang, et al.
Published: (2020-01-01)

Targeting MELK improves PD-1 blockade efficiency in cervical cancer via enhancing antitumor immunity
by: Dongjiao Wang, et al.
Published: (2024-03-01)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
by: Taiki Kurino, et al.
Published: (2020-05-01)

Enhancing Tumor Immunity with IL-12 and PD-1 Blockade: A Strategy for Inducing Robust Central Memory T Cell Responses in Resistant Cancer Model
by: Fentian Chen, et al.
Published: (2024-11-01)

Therapeutic blockade of CCL17 in obesity-exacerbated osteoarthritic pain and disease
by: Kevin Ming-Chin Lee, et al.
Published: (2025-01-01)

A novel nanomedicine integrating ferroptosis and photothermal therapy, well-suitable for PD-L1-mediated immune checkpoint blockade
by: Yujun Bao, et al.
Published: (2024-12-01)